Report Sections

See All Reports

  • HP:0011675: Arrhythmia
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0011675: Arrhythmia

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (10)


    Name (Synonyms) Correlation
    drug478 Blood samples Wiki 0.58
    drug3569 VitalConnect Vital Sign Patch Wiki 0.50
    drug695 Cardiovascular Magnetic Resonance (CMR) Imaging Wiki 0.50
    Name (Synonyms) Correlation
    drug479 Blood samples (collection of 5 mL of blood in a dry tube) Wiki 0.50
    drug689 Cardiac MRI Wiki 0.50
    drug688 Cardiac CT Wiki 0.50
    drug1136 Electrocardiogram (ECG) Wiki 0.50
    drug3420 Transthoracic echocardiogram (TTE) Wiki 0.50
    drug2115 Nasopharyngeal swabs Wiki 0.35
    drug481 Blood sampling Wiki 0.18

    Correlated MeSH Terms (9)


    Name (Synonyms) Correlation
    D001145 Arrhythmias, Cardiac NIH 1.00
    D016171 Torsades de Pointes NIH 0.50
    D001919 Bradycardia NIH 0.50
    Name (Synonyms) Correlation
    D054537 Atrioventricular Block NIH 0.50
    D001281 Atrial Fibrillation NIH 0.35
    D018754 Ventricular Dysfunction NIH 0.25
    D018487 Ventricular Dysfunction, Left NIH 0.25
    D006331 Heart Diseases NIH 0.19
    D009205 Myocarditis NIH 0.18

    Correlated HPO Terms (5)


    Name (Synonyms) Correlation
    HP:0001678 Atrioventricular block HPO 0.50
    HP:0001664 Torsade de pointes HPO 0.50
    HP:0001662 Bradycardia HPO 0.50
    Name (Synonyms) Correlation
    HP:0004757 Paroxysmal atrial fibrillation HPO 0.35
    HP:0012819 Myocarditis HPO 0.18

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 Remote Monitoring in Patients With Coronavirus Disease (COVID-19)

    The objective of the study is to assess the impact of remote cardiac and vital sign monitoring in patients with coronavirus disease (COVID-19) in the outpatient setting.

    NCT04350476
    Conditions
    1. COVID-19
    2. Cardiac Arrhythmias
    Interventions
    1. Diagnostic Test: VitalConnect Vital Sign Patch
    MeSH:Arrhythmias, Cardiac
    HPO:Arrhythmia

    Primary Outcomes

    Description: ac rhythm in patients with COVID-19 infection following treatment/discharge from MSH

    Measure: Number of different arrhythmias

    Time: 7-14 Days

    Description: Temperature of patients with COVID-19 infection following treatment/discharge from MHS

    Measure: Temperature

    Time: 7-14 Days

    Description: Oxygen saturation level in patients with COVID-19 infection following treatment/discharge from MSH

    Measure: Oxygen Saturation

    Time: 7-14 Days
    2 Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)

    The objective of the study is to estimate the frequency of cardiac arrhythmias and characterize the mode of death in patients with coronavirus disease (COVID-19). This is a single-center, retrospective/ prospective registry enrolling all COVID-19 positive patients at Mount Sinai Hospital. Patients who have been diagnosed with COVID-19 infection at Mount Sinai Hospital will be included.

    NCT04358029
    Conditions
    1. COVID 19 Cardiac
    2. COVID 16 Arrhythmia
    3. COVID 19 Death
    MeSH:Arrhythmias, Cardiac
    HPO:Arrhythmia

    Primary Outcomes

    Description: To characterize the frequency of cardiac arrhythmias in patients with COVID-19 infection

    Measure: Frequency of cardiac arrhythmias

    Time: 19 Months

    Secondary Outcomes

    Description: To characterize the mode of death in patients with COVID-19 infection

    Measure: Mode of death

    Time: 19 Months
    3 COVIDAR - International Registry on Arrhythmias in COVID-19

    BACKGROUND AND RATIONALE: There is very limited literature available on the arrhythmia occurrence in the context of an infection by the SARS-CoV2 virus. On the other hand, treatment strategies against the SARS-CoV2 virus may carry a risk of QTc prolongation and pro-arrhythmia/sudden death which may be amplified by concomitant use of other QTc-prolonging drugs and/or ion disbalances. COVIDAR is an international initiative to monitor the occurrence of arrhythmic events in the context of the SARS-CoV2 infection, to identify potential modifiable predisposing factors to reduce their incidence and to inform the best arrhythmia management options in this patient population. MAIN OBJECTIVE: To describe the incidence and type of arrhythmic events in the context of the SARS-CoV2 infection. STUDY DESIGN: patient registry (observational). Patients will not undergo any additional investigations. Only data that is generated during routine clinical care will be collected. STUDY POPULATION: Patients admitted to the hospital highly suspected of or with confirmed COVID-19.

    NCT04437901
    Conditions
    1. COVID
    2. Arrhythmia
    3. Torsades de Pointe Caused by Drug
    4. Qt Interval, Variation in
    5. Atrioventricular Block
    6. Atrial Fibrillation
    7. Bradyarrhythmia
    8. Ventricular Arrythmia
    MeSH:Atrial Fibrillation Arrhythmias, Cardiac Atrioventricular Block Bradycardia Torsades de Pointes
    HPO:Arrhythmia Atrial fibrillation Atrioventricular block Bradycardia Paroxysmal atrial fibrillation Torsade de pointes

    Primary Outcomes

    Description: Any arrhythmic event occurring in COVID-19 patients during hospital admission: Monomorphic ventricular tachycardia Polymorphic ventricular tachycardia/Torsades de pointes (non-sustained) Ventricular fibrillation AV-block Severe bradycardia, symptomatic and/or requiring treatment New-onset atrial fibrillation Other

    Measure: Arrhythmia

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

    Secondary Outcomes

    Description: Categorical variable collecting the patient's underlying rhythm at baseline, on treatment and in case of arrhythmic adverse events): sinus rhythm, atrial fibrillation/flutter, other

    Measure: Electrocardiographic changes - Underlying rhythm

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

    Description: Collected as a categorical (normal, 1st-, 2nd- or 3rd degree AV block) and a continuous (PR duration in ms) at baseline, on treatment and in case of arrhythmic adverse events)

    Measure: Electrocardiographic changes - Atrioventricular conduction

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

    Description: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)

    Measure: Electrocardiographic changes - QRS duration

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

    Description: Collected as a categorical variable (not present, type 1 or type 2) at baseline, on treatment and in case of arrhythmic adverse events)

    Measure: Electrocardiographic changes - presence of Brugada QRS pattern

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

    Description: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)

    Measure: Electrocardiographic changes - QTc duration

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

    Description: Kalium, magnesium and calcium collected as continuous variables at baseline, on treatment and in case of arrhythmic adverse events). Will be reported as a categorical variable (presence/absence) of electrolyte misbalance

    Measure: Laboratory abnormalities - electrolyte misbalance

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

    Description: Cardiac CK, troponin T and/or troponin I (where available) collected as a continuous variable at baseline, on treatment and in case of arrhythmic adverse events)

    Measure: Laboratory abnormalities - cardiac biomarkers

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

    Description: Creatinine clearance at baseline, on treatment and in case of arrhythmic adverse events)

    Measure: Laboratory abnormalities - renal function

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

    Description: Liver enzymes collected at at baseline, on treatment and in case of arrhythmic adverse events)

    Measure: Laboratory abnormalities - liver function

    Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months
    4 COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae (COLUMBIA CARDS) Registry

    COLUMBIA CARDS is a pilot study to understand how COVID-19 affects the heart. It is known that COVID-19 can affect the heart in different ways. COLUMBIA CARDS is studying why some COVID-19 survivors develop clinical conditions such as heart inflammation, fluid buildup, blood clots, and other cardiac problems during or after their COVID-19 illness, and why other ones do not. In this study, we will use cardiovascular magnetic resonance (CMR) and transthoracic echocardiography (TTE) to better understand the impact of COVID-19 on the heart.

    NCT04661657
    Conditions
    1. Covid19
    2. Cardiac Disease
    3. Cardiac Arrhythmia
    4. Myocarditis
    5. Left Ventricular Dysfunction
    Interventions
    1. Other: Transthoracic echocardiogram (TTE)
    2. Other: Cardiovascular Magnetic Resonance (CMR) Imaging
    MeSH:Arrhythmias, Cardiac Ventricular Dysfunction Heart Diseases Ventricular Dysfunction, Left Myocarditis
    HPO:Arrhythmia Myocarditis

    Primary Outcomes

    Description: Percentage of myocardium demonstrating late gadolinium enhancement by cardiac magnetic resonance (CMR) imaging, determined using Circle cvi42 software.

    Measure: Percentage of myocardium demonstrating late gadolinium enhancement

    Time: Up to 2 hours

    Description: Extracellular volume fraction measured by CMR imaging. ECV determined using Circle cvi42 software and using formula ECV = (1-hematocrit) × (Δ(1/T1myocardium)/Δ(1/T1blood)).

    Measure: Extracellular Volume (ECV) Fraction

    Time: Up to 2 hours

    Description: Left ventricular ejection fraction (percent ejection fraction) by CMR imaging and determined using Circle cvi42 software.

    Measure: Left Ventricular Ejection Fraction

    Time: Up to 2 hours

    HPO Nodes


    HP:0011675: Arrhythmia
    Genes 671
    TLL1 TGIF1 DSP ABCA12 SCN9A ND6 PEX3 PEX6 TRNL1 HSPG2 NODAL MEN1 TRNK GTF2IRD1 TRNC CAVIN1 TMEM43 TTN KCND3 RANGRF TRDN RASA2 SHH CACNA1C RET LAMA3 RYR2 SPECC1L IKZF1 PPOX UCP2 TRNS2 DSG2 SDHD KCNE2 BMP2 GNAI2 AKT1 GNB5 NOS1AP CAV3 GPD1L GNA11 KCNQ1 CACNA1S KCNH2 ND1 KCNJ11 FMO3 CALM2 HLA-DPA1 TMEM43 GATA6 GATA4 LMNA APOB RIT1 SCNN1G PRKAG2 MYL3 SYNE1 ABCC9 AKAP9 NKX2-5 KCNE5 FGF8 SCN3B GAS1 SDHB COX3 CACNB2 FOXH1 CLIP2 JUP TAZ TBX3 CRLF1 CALM2 KCNE1 MYOZ2 DES CAV3 DST SGO1 CNBP KCNE1 EMD COX1 DLL1 SIX3 POLG2 ELN PTEN KCND3 HJV SLC19A2 MYH6 ABCA3 PEX6 ND4L HLA-DPB1 SCN5A CASQ2 TGFBR1 HFE ND2 SLC40A1 GNB5 FOXH1 SLC25A20 CBL DLST CDON ND6 TTR RRAS2 TSC1 PPOX GPX4 DNMT3A GAS1 FOXC2 ECE1 GJA1 CREBBP TRNW FBP1 GDNF CTLA4 SCN1B EPAS1 SCN5A FHL1 GJA1 HLA-B KCNE1 GPX4 NDUFB11 CDH23 DAXX SNTA1 CYTB GLA CDON RAF1 TRNW MTO1 CALM1 BANF1 GATA5 CBL GYG1 SHH DISP1 TMEM70 ZIC2 SLC12A3 PYGM HNF4A ND5 NF1 MADD CSRP3 DISP1 HCN4 SRY SDHAF2 NDUFB11 SLC25A4 SCN5A ENPP1 GSN FOXH1 ACADVL TDGF1 KCNQ1 PRTN3 VPS33A KCNQ1 MYH6 SDHD HRAS XK TTN TRPM4 MFAP5 SLC25A20 TRNS1 GLI2 FGF8 SDHD TRNH CASQ2 PAX8 COX1 CALM3 RRAS CRELD1 LMNA SCN5A TPM1 SCN5A FGFR1 ND4L NAA10 DES RYR1 ELP1 CACNA1S FHL1 KIF1B LMNA TBX3 DPP6 ND1 LMNA SOS2 ACADVL KCNJ18 KCNJ2 SLC19A2 ND4 ND5 HTRA2 CTNNA3 TRPM4 CPT1A PCCB TRNF TPM2 KIF20A TECRL GTPBP3 ELP1 SCNN1A DISP1 KRAS STAG2 UQCRFS1 SALL4 SIX3 TRNQ ELN HNF1A MAX ATP6 PLN PCCA TCAP TRNS1 MRAS SCO1 TSPYL1 MYLK2 PEX13 ERCC8 TRDN COQ9 KCNH2 FLAD1 MYL2 TBX20 TRNE TRPM4 ZIC2 SLMAP KYNU CSF2RA LAMA2 ISCU CLCF1 SCN4B CYTB GATA4 KCNQ1 KCNJ2 HMBS GLA KCNQ1 FBXL4 FGF8 BRAF ABCC8 SHH BVES CALM3 NKX2-5 HCN4 SDHC HBB CITED2 LDLRAP1 MYBPC3 CALM3 PTPN22 NODAL MRPS14 PTCH1 ZIC2 SDHB TRNF LMNA KCNE2 GPD1L CACNB2 DLL1 SCN4A ND1 HMGCL KCNJ2 LAMP2 DTNA PTPN22 PEX14 SFTPC CIZ1 TRNS2 CACNA2D1 ABCC9 SDHB LDLR ATRX TGFB3 CDON PTPN11 GABRA3 SOS1 SCNN1B NPPA KCNE3 SCN5A PTCH1 HCN4 MGME1 WIPI2 KCNQ1 KCNJ2 GLI2 NKX2-5 ATP6 SYNE2 TNXB SCN1B NKX2-5 TAB2 PCSK9 POLG2 IFNG JPH2 PEX7 PHYH SCN1B IDS FGFR1 TGFBR2 PLN SCN9A GALC SFTPB ACTC1 RET TNNT2 JUP ACTC1 KCNJ5 TSHR GNB5 SEMA3A VHL CASQ2 PPA2 TAB2 CPOX CPOX GATA6 RYR2 MYH7 TTPA EYA4 KIF1B PEX5 ND2 KCNK3 SLC2A10 CACNA1C GBA CPT2 TRNK MTFMT KCNA5 EFEMP2 SCN5A TOR1A COQ4 TBL2 KCNQ1 BMP2 TRDN SYNE2 FLNC PIK3CA TSPYL1 LRP6 CYTB WIPF1 HCCS HCCS SDHD AKAP10 LMNA NDUFB11 TLL1 RFC2 NDUFS2 GYG1 LAMC2 LMNA MADD ND4 RRM2B LMNA LIMK1 DMD TECRL DSP TPM3 GTPBP3 TWNK CALM1 SIX3 CACNA1S GLI2 CSF2RB PSMB8 CACNA1C SCN4B TANGO2 NPPA GAA AKAP9 ND6 DMD FHL1 CALM1 CALM2 SCN1B SMAD3 BRAT1 MRPL12 CDON IDS SRSF2 ANK2 CACNA2D1 ND1 RAF1 TNNI3K PEX16 TNNT2 SOX10 RYR1 DNAJC19 RAF1 SCNN1G TRNQ SDHB SDHC PRKAG2 ZIC2 CITED2 DNMT3A FLNC PEX1 COX2 FOXH1 TNNI3 HADHA APRT ND6 ACTN2 TNNC1 DSP SCN3B KCNH2 PTPN11 TSC2 COX3 PEX12 GPC3 GATAD1 FBP1 ACAD9 FGF8 HBB CDH2 POLG HADHB TMEM127 DMPK KYNU PRDM16 SLC12A3 ANK2 SCNN1A TGIF1 SCN5A KCNJ8 RBM20 VHL HFE PEX2 PEX10 SMC1A KCNE2 HLA-B TBX5 TDGF1 CLCNKB PGM1 COX7B A2ML1 PTCH1 TNNI3 COL4A1 HMBS KCNE1 CLIC2 GLI2 TP53 SDHA GAS1 LMNA TET2 GAS1 NRAS ASXL1 ABCG5 WAS DMPK CASR PEX26 MYH7 PSAP SCN5A USP18 COX3 RYR2 RET TOP3A TGIF1 GLUL SCN10A KCNQ1 MGME1 ABCC6 SCNN1B GTF2I MEFV TWNK SNTA1 SMAD3 LAMB3 MYH7 ERCC6 MYPN DSC2 LIPT1 ACADM PTCH1 TRNV TMEM127 RUNX1 LDB3 PRKAG2 TBX20 TDGF1 MYL4 COX2 MDH2 CALM1 HFE TGIF1 PHOX2B CAV3 CPT1A MAX ATP6 TMEM70 TRDN LARS2 EMD TDP2 NEXN ND5 CACNA1S TSHR ND4 SCN2B PKP2 NUP155 SCN5A MYH7 TDGF1 PEX19 SCN10A TRNL1 ACTC1 PEX5 DLL1 KCNH2 SHH TET2 CPT2 SIX3 MYPN KCNJ5 BMP2 ALG10B GJA5 ND5 SDHD STAG2 SCN2B GPC4 FH GDAP1 GNAQ GFM2 COX1 FOXC2 CACNA1C EP300 KCNJ18 TNNI3 LZTR1 HLA-DRB1 VHL PEX11B TLL1 SCNN1A NODAL KCNE3 PKP2 MYPN BAZ1B DLL1 VHL JUP TANGO2 CACNA1D SLC25A11 RAF1 RET PEX1 CLIC2 COX3 COX7B ABCC9 CPT2 ABCG8 NR2F2 CAV3 NODAL TAB2 TMEM43 CYTB GJA5 BTNL2 DISP1 NAA10 TRNL1
    Protein Mutations 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0011675: Arrhythmia
    Genes 671
    TLL1 TGIF1 DSP ABCA12 SCN9A ND6 PEX3 PEX6 TRNL1 HSPG2 NODAL MEN1 TRNK GTF2IRD1 TRNC CAVIN1 TMEM43 TTN KCND3 RANGRF TRDN RASA2 SHH CACNA1C RET LAMA3 RYR2 SPECC1L IKZF1 PPOX UCP2 TRNS2 DSG2 SDHD KCNE2 BMP2 GNAI2 AKT1 GNB5 NOS1AP CAV3 GPD1L GNA11 KCNQ1 CACNA1S KCNH2 ND1 KCNJ11 FMO3 CALM2 HLA-DPA1 TMEM43 GATA6 GATA4 LMNA APOB RIT1 SCNN1G PRKAG2 MYL3 SYNE1 ABCC9 AKAP9 NKX2-5 KCNE5 FGF8 SCN3B GAS1 SDHB COX3 CACNB2 FOXH1 CLIP2 JUP TAZ TBX3 CRLF1 CALM2 KCNE1 MYOZ2 DES CAV3 DST SGO1 CNBP KCNE1 EMD COX1 DLL1 SIX3 POLG2 ELN PTEN KCND3 HJV SLC19A2 MYH6 ABCA3 PEX6 ND4L HLA-DPB1 SCN5A CASQ2 TGFBR1 HFE ND2 SLC40A1 GNB5 FOXH1 SLC25A20 CBL DLST CDON ND6 TTR RRAS2 TSC1 PPOX GPX4 DNMT3A GAS1 FOXC2 ECE1 GJA1 CREBBP TRNW FBP1 GDNF CTLA4 SCN1B EPAS1 SCN5A FHL1 GJA1 HLA-B KCNE1 GPX4 NDUFB11 CDH23 DAXX SNTA1 CYTB GLA CDON RAF1 TRNW MTO1 CALM1 BANF1 GATA5 CBL GYG1 SHH DISP1 TMEM70 ZIC2 SLC12A3 PYGM HNF4A ND5 NF1 MADD CSRP3 DISP1 HCN4 SRY SDHAF2 NDUFB11 SLC25A4 SCN5A ENPP1 GSN FOXH1 ACADVL TDGF1 KCNQ1 PRTN3 VPS33A KCNQ1 MYH6 SDHD HRAS XK TTN TRPM4 MFAP5 SLC25A20 TRNS1 GLI2 FGF8 SDHD TRNH CASQ2 PAX8 COX1 CALM3 RRAS CRELD1 LMNA SCN5A TPM1 SCN5A FGFR1 ND4L NAA10 DES RYR1 ELP1 CACNA1S FHL1 KIF1B LMNA TBX3 DPP6 ND1 LMNA SOS2 ACADVL KCNJ18 KCNJ2 SLC19A2 ND4 ND5 HTRA2 CTNNA3 TRPM4 CPT1A PCCB TRNF TPM2 KIF20A TECRL GTPBP3 ELP1 SCNN1A DISP1 KRAS STAG2 UQCRFS1 SALL4 SIX3 TRNQ ELN HNF1A MAX ATP6 PLN PCCA TCAP TRNS1 MRAS SCO1 TSPYL1 MYLK2 PEX13 ERCC8 TRDN COQ9 KCNH2 FLAD1 MYL2 TBX20 TRNE TRPM4 ZIC2 SLMAP KYNU CSF2RA LAMA2 ISCU CLCF1 SCN4B CYTB GATA4 KCNQ1 KCNJ2 HMBS GLA KCNQ1 FBXL4 FGF8 BRAF ABCC8 SHH BVES CALM3 NKX2-5 HCN4 SDHC HBB CITED2 LDLRAP1 MYBPC3 CALM3 PTPN22 NODAL MRPS14 PTCH1 ZIC2 SDHB TRNF LMNA KCNE2 GPD1L CACNB2 DLL1 SCN4A ND1 HMGCL KCNJ2 LAMP2 DTNA PTPN22 PEX14 SFTPC CIZ1 TRNS2 CACNA2D1 ABCC9 SDHB LDLR ATRX TGFB3 CDON PTPN11 GABRA3 SOS1 SCNN1B NPPA KCNE3 SCN5A PTCH1 HCN4 MGME1 WIPI2 KCNQ1 KCNJ2 GLI2 NKX2-5 ATP6 SYNE2 TNXB SCN1B NKX2-5 TAB2 PCSK9 POLG2 IFNG JPH2 PEX7 PHYH SCN1B IDS FGFR1 TGFBR2 PLN SCN9A GALC SFTPB ACTC1 RET TNNT2 JUP ACTC1 KCNJ5 TSHR GNB5 SEMA3A VHL CASQ2 PPA2 TAB2 CPOX CPOX GATA6 RYR2 MYH7 TTPA EYA4 KIF1B PEX5 ND2 KCNK3 SLC2A10 CACNA1C GBA CPT2 TRNK MTFMT KCNA5 EFEMP2 SCN5A TOR1A COQ4 TBL2 KCNQ1 BMP2 TRDN SYNE2 FLNC PIK3CA TSPYL1 LRP6 CYTB WIPF1 HCCS HCCS SDHD AKAP10 LMNA NDUFB11 TLL1 RFC2 NDUFS2 GYG1 LAMC2 LMNA MADD ND4 RRM2B LMNA LIMK1 DMD TECRL DSP TPM3 GTPBP3 TWNK CALM1 SIX3 CACNA1S GLI2 CSF2RB PSMB8 CACNA1C SCN4B TANGO2 NPPA GAA AKAP9 ND6 DMD FHL1 CALM1 CALM2 SCN1B SMAD3 BRAT1 MRPL12 CDON IDS SRSF2 ANK2 CACNA2D1 ND1 RAF1 TNNI3K PEX16 TNNT2 SOX10 RYR1 DNAJC19 RAF1 SCNN1G TRNQ SDHB SDHC PRKAG2 ZIC2 CITED2 DNMT3A FLNC PEX1 COX2 FOXH1 TNNI3 HADHA APRT ND6 ACTN2 TNNC1 DSP SCN3B KCNH2 PTPN11 TSC2 COX3 PEX12 GPC3 GATAD1 FBP1 ACAD9 FGF8 HBB CDH2 POLG HADHB TMEM127 DMPK KYNU PRDM16 SLC12A3 ANK2 SCNN1A TGIF1 SCN5A KCNJ8 RBM20 VHL HFE PEX2 PEX10 SMC1A KCNE2 HLA-B TBX5 TDGF1 CLCNKB PGM1 COX7B A2ML1 PTCH1 TNNI3 COL4A1 HMBS KCNE1 CLIC2 GLI2 TP53 SDHA GAS1 LMNA TET2 GAS1 NRAS ASXL1 ABCG5 WAS DMPK CASR PEX26 MYH7 PSAP SCN5A USP18 COX3 RYR2 RET TOP3A TGIF1 GLUL SCN10A KCNQ1 MGME1 ABCC6 SCNN1B GTF2I MEFV TWNK SNTA1 SMAD3 LAMB3 MYH7 ERCC6 MYPN DSC2 LIPT1 ACADM PTCH1 TRNV TMEM127 RUNX1 LDB3 PRKAG2 TBX20 TDGF1 MYL4 COX2 MDH2 CALM1 HFE TGIF1 PHOX2B CAV3 CPT1A MAX ATP6 TMEM70 TRDN LARS2 EMD TDP2 NEXN ND5 CACNA1S TSHR ND4 SCN2B PKP2 NUP155 SCN5A MYH7 TDGF1 PEX19 SCN10A TRNL1 ACTC1 PEX5 DLL1 KCNH2 SHH TET2 CPT2 SIX3 MYPN KCNJ5 BMP2 ALG10B GJA5 ND5 SDHD STAG2 SCN2B GPC4 FH GDAP1 GNAQ GFM2 COX1 FOXC2 CACNA1C EP300 KCNJ18 TNNI3 LZTR1 HLA-DRB1 VHL PEX11B TLL1 SCNN1A NODAL KCNE3 PKP2 MYPN BAZ1B DLL1 VHL JUP TANGO2 CACNA1D SLC25A11 RAF1 RET PEX1 CLIC2 COX3 COX7B ABCC9 CPT2 ABCG8 NR2F2 CAV3 NODAL TAB2 TMEM43 CYTB GJA5 BTNL2 DISP1 NAA10 TRNL1
    Protein Mutations 0

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook